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AMD473 is a novel sterically hindered platinum cytotoxic with demonstrated ability to overcome acquired resistance to cisplatin in
vitro and in human tumour xenografts. A single-agent dose escalating Phase I study was performed. AMD473 was initially administered
intravenously as a 1h infusion every 21 days to patients with advanced solid tumours. In total, 42 patients received a total of 147
cycles (median 3, range 1–8) of treatment at doses of 12, 24, 48, 96, 110, 120, 130, and 150mgm
 2. Dosing intervals of 21 and 28
days were explored at the recommended dose. Neutropenia and thrombocytopenia proved dose limiting. Other toxicities included
moderate nausea, vomiting, anorexia, and a transient metallic taste. There was no significant alopecia. The maximum tolerated dose
was 150mgm
 2. Plasma pharmacokinetics were linear. Two patients with heavily pretreated ovarian cancer showed partial response.
Five patients (mesothelioma, ovary, nonsmall cell lung, and melanoma) showed prolonged stable disease. AMD473 demonstrates
encouraging activity in patients, including those with prior platinum exposure. Toxicity is predictable with linear pharmacokinetics, as
was predicted by preclinical studies. A dose of 120mgm
 2 every 21 days is recommended for Phase II evaluation although there is
evidence that chemo-naive patients and those of good performance status may tolerate a higher dose.
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While cisplatin is used widely in the clinic to treat many tumour
types, clinical utility is limited by two major factors: (i) drug
resistance, either intrinsic or acquired, and (ii) the principal dose-
limiting side effects of nephrotoxicity and neurotoxicity. Unfortu-
nately, although the initial tumour response to cisplatin in many
tumours may be high, most patients will nevertheless relapse and
die of their disease.
AMD473 was primarily designed to overcome one of the known
mechanisms of platinum resistance: detoxification by intracellular
thiols, through the introduction of a bulky methylpyridine ring to
provide steric hindrance to direct interaction with platinum
(Figure 1) (Raynaud et al, 1997). Preclinical evaluation of
AMD473 confirmed that this drug was also able to overcome
platinum complex resistance in cell lines with high levels of
glutathione (GSH) (Holford et al, 1998a, b). In studies with human
ovarian cell lines, it has been shown that increasing levels of
reduced GSH are associated with increasing platinum resistance
(Mistry et al, 1991). In addition, lower levels of glutathione
S-transferase (GST) activity have been shown to be associated with
enhanced clinical response to platinum-based chemotherapy in
head and neck cancer (Nishimura et al, 1996). Furthermore,
AMD473 was able to overcome resistance because of decreased
cellular uptake of drug in some cell lines or enhanced DNA repair/
increased tolerance of platinum adducts in others (Holford et al,
1998a, b). AMD473 forms interstrand cross-links, but does so at a
rate intermediate to that of cisplatin and carboplatin, because of its
reduced reactivity relative to cisplatin (Holford et al, 1998a, b).
Using a Taq polymerase stop assay to identify the site of DNA
adducts, a novel pattern of DNA binding was identified in pBR322
DNA after incubation with 10 and 100mM AMD473 for 2h (Holford
et al, 1998a). This finding may also in part account for the
observed capability of AMD473 to circumvent adduct tolerance
and DNA-repair mechanisms associated with resistance to
cisplatin.
Preclinical pharmacology studies in mice have demonstrated
that the maximum tolerated dose (MTD) is 45mgkg
 1 given as a
single intraperitoneal administration, with the dose-limiting
toxicity (DLT) being myelosuppression. Owing to the limited
aqueous solubility of AMD473, preclinical toxicology studies
were conducted by intraperitoneal injection following a pharmaco-
kinetic demonstration of equivalent bioavailability of intraperito-
neal and intravenous administration. No renal toxicity was
observed (Pre-clinical toxicology report – CR UK, Drug data file,
1997).
Antitumour activity was noted in several tumour models
including human ovarian carcinoma xenografts with acquired
resistance to cisplatin (CH1cisR) and carboplatin (HX110P). In
head-to-head experiments, AMD473 showed an improved anti-
tumour effect compared with cisplatin and satraplatin (JM216, bis-
acetato-ammine-dichloro-cyclohexylamine platinum IV) against
the CH1cisR xenograft (34 days growth delay vs 10.4 and 3.5 days,
respectively). The antitumour activity was similar when AMD473
was given daily for 5 days every week for 4 weeks (60mgkg
 1 for 4
weeks) or by weekly administration (300mgkg
 1 every 7 days for
4 weeks) (Raynaud et al, 1997).
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sOn the basis of the preclinical antitumour activity seen with
AMD473, especially in models with acquired platinum resistance,
the lack of nonhaematological toxicity, and the activity via the oral
route, the drug was taken into clinical development. This Phase I
trial commenced at the Royal Marsden Hospital under the auspices
of the Cancer Research UK Phase I/II Committee. The initial
schedule chosen was a short intravenous infusion given once every
3 weeks. A pharmacokinetically guided dose escalation scheme was
used, for several reasons. Firstly, there is no evidence of
metabolism of AMD473 in vivo and thus the free platinum AUC
(area under the concentration vs time curve) should reflect the
biologically important species in both man and mouse. Secondly,
the previous experience with cisplatin and carboplatin has
demonstrated the close relation between the AUC at MTD in the
mouse and the AUC in humans at MTD (Van Hennik et al, 1987).
It was hoped that this approach would reduce the number of dose
escalations required to reach MTD.
METHODS
Study design
The trial was an open-label, dose-escalating, single-centre Phase I
trial. The study protocol and patient information sheet were
approved by the Royal Marsden Research Ethics Committee. The
study was managed and conducted in accordance with the
principles of the International Committee on Harmonisation Good
Clinical Practice and with the Cancer Research UK’s Standard
Operating Procedures. The objectives of the trial were to determine
(1) the MTD, (2) the DLTs, (3) the pharmacokinetics in humans,
(4) evidence of antitumour activity, and (5) pharmacokinetic and
pharmacodynamic relations when the drug was administered as a
short infusion intravenously over 1–2h, depending on the volume.
The starting dose was 12mgm
 2 which was one-tenth of the
MTD/lethal dose in 10% of mice (LD10) (Raynaud et al, 1997).
Study population
All patients were required to have a pathologically confirmed
diagnosis of a malignant solid tumour proven refractory to
conventional treatment or for which no conventional treatment is
standard. Additional eligibility criteria included a WHO perfor-
mance status of 0–2, a life expectancy of greater than 3 months,
and age X18 years. Previous anticancer chemotherapy had to be
discontinued for at least 4 weeks prior to entry into the study or 6
weeks in the case of pretreatment with mitomycin-C or
nitrosureas. Patients were required to have recovered from all
toxicity arising from prior therapy, with no evidence of serious
concomitant medical problems or hearing loss, and should have
completed any large field radiotherapy at least 4 weeks before
study entry. All patients had to have acceptable bone marrow, liver
and renal function as defined by WBC X3.0 10
9l
 1, neutrophil
count X1.5 10
9l
 1, platelet count X100 10
9l
 1, bilirubin
p25mmoll
 1; ALT, ALP p1.25 ULN or p5 ULN in the
presence of metastases and a creatinine clearance (as measured
by
51Cr EDTA clearance or calculated according to the method of
Cockcroft and Gault (1976)). All patients were asked to sign
written informed consent prior to participation.
End points
The treatment was to be given every 3 weeks and patients could
continue to receive further cycles while there was no evidence of
disease progression or significant toxicity. Dose escalation was to
be performed according to the pharmacological guided dose
escalation method based on the ultrafiltrable AUC. Using this
method, dose levels would be doubled until the AUC of
ultrafiltrable platinum was X40% of the mouse MTD in two out
of three patients, or there was grade II drug-related toxicity (not
including nausea or vomiting and alopecia) seen in 41 patient at a
particular dose level. Thereafter, dose escalations would be
according to the modified Fibonacci method (60, 40, 30%) until
MTD was reached (Schneiderman in Simon, 1993). At each dose,
three patients would be treated unless a need for expansion was
indicated, for example, drug-related grade II organ specific toxicity
or grade III antiproliferative toxicity (myelosuppression, muco-
sitis, or diarrhoea).
The initial patient at each dose level was observed for 3 weeks
prior to further patients being enrolled. Escalation to the next dose
level could only proceed when all three patients at the previous
level had been observed for 3 weeks. Full pharmacokinetic data
were reviewed prior to each dose escalation. The MTD was defined
as the dose at which three or more of six patients suffered DLT. In
turn, DLT was defined as the occurrence of: grade 4 neutropenia of
X5 days duration; other grade 3 antiproliferative toxicities such as
thrombocytopenia, neutropenic sepsis, diarrhoea requiring hydra-
tion; or Xgrade 2 organ-specific toxicity. The dose recommended
for the Phase II study would then be chosen, either the dose prior
to that defined as MTD or an intermediate dose. Provided
myelosuppression proved dose-limiting the Phase II dose would
be defined as that which could be delivered safely and repeatedly
without significant incidence of grade 4 thrombocytopenia or
grade 4 neutropenia of more than 5 days duration.
Study drug
AMD473 was supplied as a sterile 0.4mgml
 1 solution in 0.9%
saline, as 200mg (500ml) bags or 10mg (25ml) ampoules, by the
Cancer Research UK Formulation Unit, Department of Pharma-
ceutical Sciences, University of Strathclyde. The drug solution was
further diluted in 0.9% saline for administration. At doses up to
200mg, 500ml was infused, and for doses greater than 200mg,
1000ml was infused with treatment given over an hour indepen-
dent of volume. The final reconstituted formulation at concentra-
tions of 0.4mgml
 1 or lower is stable for at least 6 months when
kept at room temperature and protected from light.
Pharmacokinetic studies
Pharmacokinetic blood sampling was performed in all patients
during the first course of treatment. Blood was collected into
heparinised tubes for total and ultrafiltrable platinum analysis at
time zero, 30min, 1 and 2h into the infusion; and then 5, 15, 30,
45, 60min, 2, 4, 6, 9, 12, 24, 48, 72h, and day 8 after infusion. The
samples were centrifuged at 2000g for 5min at 41C to prepare the
plasma. Two aliquots were stored for total platinum analysis in
plasma and plasma ultrafiltrates were subsequently prepared using
two Amicon Centrifree Filters (30000MW cutoff) per sample. The
filters were centrifuged at 2000g for 20min at 41C and the
ultrafiltrates stored in liquid nitrogen prior to analysis. Urine was
collected for three 12-h time periods until 36h after the infusion
started. The volumes were recorded and aliquots were stored
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Figure 1 AMD473 structure.
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sfrozen for platinum analysis. Pharmacokinetic analysis was
performed using WinNonlin (Pro model 202) using noncompart-
mental analysis.
Toxicity and response assessment
Toxicity was assessed at the visits to the clinic using the National
Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)
Common Toxicity Criteria V1 and supplemented through the use
of daily diary cards. Patients were assessed for clinical response
prior to each treatment and with radiological evaluation every two
cycles. Responses were graded according to the WHO criteria for
response (WHO, 1979). Audiometry and creatinine clearance
(according to the method of Cockcroft and Gault) was reviewed
prior to each cycle of treatment.
RESULTS
Patient accrual
In total, 42 patients were entered in the study between 10
November 1997 and 14 December 1999. The patients’ demographic
and baseline characteristics are listed in Table 1. The number of
patients assigned to each dose level is shown in Table 2. A total of
147 cycles were administered and the median number of cycles was
three (range 1–8). In all, 41 (98%) patients had received prior
chemotherapy before entering the study. The median time
(exclusive) between the last chemotherapy end date and the first
cycle start date was 22 weeks (range of 4–86 weeks). Of these 41
patients who had received prior chemotherapy, the median
number of regimens per patient was four. In all, 37 patients had
received prior platinum chemotherapy: 14 patients started their
first cycle of study drug treatment less than 6 months after
stopping platinum chemotherapy, 12 patients within 6 months to 1
year, and 11 patients after more than 1 year.
Toxicity
From a starting dose of 12mgm
 2, the dose of AMD473 was
doubled until grade 2 drug-related haematological toxicity was
observed in one out of three patients treated at 96mgm
 2. At this
dose, the AUC for free platinum was 440% of the AUC of free
platinum observed in mice at the MTD. Therefore, the treatment
dose was escalated to 130mgm
 2, which correlated with a
projected free platinum AUC equivalent to that at the mouse
MTD. At this dose, DLT was observed in three patients; hence
MTD was reached in this cohort. Treatment was planned to be
delivered once every 3 weeks, but in the patient group recruited at
130mgm
 2 it could only be delivered every 4–5 weeks because of
myelosuppression (predominantly thrombocytopenia). It was
therefore decided to explore intermediate doses. At 110mgm
 2
(every 4 weeks), no DLT was observed in five patients leading to
re-escalation to 120mgm
 2 (every 4 weeks), where again DLT was
not seen in three patients.
It was noted that the patients who had received the study drug at
dose level 130mgm
 2 were very heavily pretreated and some had
borderline performance status. Given the lack of toxicity in
patients at dose levels 110 and 120mgm
 2, a further six patients
were enrolled at 150mgm
 2 (every 4 weeks) who had not been
heavily pretreated (no more than two previous cycles of
chemotherapy or one course of carboplatin) and who had a good
performance status. At this dose level, three of six patients
developed DLT, indicating a definite MTD. Further patients were
subsequently recruited at the 120mgm
 2 dose level, using the
original 3 weekly interval. Thus, 14 patients in total were treated at
120mgm
 2: 11 at a 3 weekly interval and three patients who
received the drug at a 4 weekly interval.
In all, 15 patients had significant treatment delay or dose
reductions because of drug-related toxicities, primarily myelosup-
pression, at dose levels of 96mgm
 2 or above. The grade 3/4
haematological toxicities, as seen in cycle one as well as overall, are
listed in Table 3. Thrombocytopenia was the most commonly
observed toxicity in 30 patients (71%) who experienced 103
episodes of thrombocytopenia, of which 24% were Xgrade 3. At
110, 120, 130, and 150mgm
 2, thrombocytopenia grade 3 or 4
occurred in 10, 12, 25, and 46% of cycles. One patient, who had
adenocarcinoma of the ovary, experienced fatal grade 4 rectal
bleeding after receiving her second cycle of the study drug. After
an initial cycle of treatment at 130mgm
 2, during which she
required a platelet transfusion for grade 4 thrombocytopenia, she
went on to receive a second cycle at the reduced dose of
96mgm
 2. Grade 4 rectal bleeding associated with grade 4
thrombocytopenia, started 12 days after administration of this
second cycle and the patient died. There was evidence of
progressive disease and no leukopenia; hence it was believed that
thrombocytopenia had occurred either because of disseminated
intravascular coagulation or simply because of consumption as a
result of persistent bleeding.
Neutropenia was seen at all the higher dose levels with 16, 10, 17,
and 23% of cycles complicated by grade 3 or 4 neutropenia at 110,
120, 130, and 150mgm
 2, respectively. In all, 34 patients (81%)
experienced lymphocytopenia, and of these episodes 49% were
Xgrade 3. Anaemia was generally mild (grades 1 and 2) and
tended to occur in later cycles, suggesting a cumulative effect.
Table 1 Patient characteristics
Patient no. 42
Gender (M/F) 16/26
Age (median range) 53 (33–71)
PS (WHO)
03
12 2
21 7
Tumour type
Ovary 10
Nonsmall cell lung 9
Mesothelioma 7
Head and neck 6
Colon 3
Other 7
Prior treatment
Prior radiotherapy 19 (45%)
Prior chemotherapy 41 (98%)
Prior hormonal, biological or immunotherapy 15 (38%)
Previous platinum 37 (88%)
Table 2 Dose escalation – listing of dose levels treated, cycle length, and
incidence of DLT
Dose
(mgm
 2)
Patient
number
Duration of
one cycle
(days)
Number of
patients
experiencing DLT
12 3 21 0
24 3 21 0
48 3 21 0
96 3 21 0
130 5 28 3
110 5 28 0
120 3 28 0
150 6 28 3
120 11 21 1
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sNone of the patients treated at the two lowest doses (i.e. 12 and
24mgm
 2) received prophylactic antiemetics, although two out of
three patients at 24mgm
 2 required symptomatic treatment. One
of three patients at 48mgm
 2, and two of three patients at
96mgm
 2, received prophylactic antiemetics. At 110mgm
 2 and
above, prophylactic antiemetics were given routinely. Nausea (62%
of patients), vomiting (36% of patients), and anorexia (31% of
patients) were the most frequent gastrointestinal side effects.
Nausea and vomiting were generally controlled by granisetron
1mg with dexamethasone 8mg prior to therapy, although some
patients did require supplemental metoclopramide or dexametha-
sone for delayed symptoms.
No drug-related nephrotoxicity was observed, although two
patients developed a rise in creatinine because of ureteric
obstruction secondary to pelvic disease. Changes in the ECG were
seen in two patients after one and three cycles, respectively, but
were not clinically significant. One patient with nonsmall cell lung
cancer developed grade 3 elevation of bilirubin after two cycles of
treatment, which was possibly related to AMD473. Nine episodes
of infection in six patients were considered to be drug-related,
including four episodes of candidiasis, two episodes of cellulitis of
the left neck, two chest infections, and one urinary tract infection.
Only one of these occurred in the context of neutropenia. Malaise
and fatigue were reported by 21 patients (50%) and 70% of these
episodes were considered almost certainly, probably or possibly
related to the treatment. Hypokalemia was reported in 18 patients,
and considered to be drug-related in six (one at 120mgm
 2 and
five at 150mgm
 2). All episodes were grade 1 or 2 and all resolved.
No reproducible significant changes in audiometry were seen. In
all, 14 episodes of grade 1/2 abnormal taste sensation occurred in
seven patients with an onset time of between 7 and 21 days after
dosing. At the two highest dose levels (120 and 150mgm
 2), the
mean number of cycles received was 3.5, with three patients
receiving four cycles and four patients receiving six cycles. There
was no evidence of sensory or motor neuropathy.
Pharmacokinetics
Platinum levels were measured in plasma, plasma ultrafiltrate, and
urine by atomic absorption spectrophotometry using a previously
validated method adapted for clinical use (Raynaud et al, 1997).
The lower limit of quantification (LLQ) of the pharmacokinetic
assay was 5ngml
 1. The mean values for the pharmacokinetic
parameters measured are presented in Tables 4 and 5 for
ultrafiltrate (free) and plasma (total) platinum, respectively.
Samples were obtained from 41 of 42 patients. The ultrafiltrable
platinum AUC increased linearly with dose (r
2¼0.79 Po0.0001)
(Figure 2). There was one outlier, patient 24 treated at 120mgm
 2,
with an AUClast¼26629hmgl
 1 (data point not shown on graph
as outside the range). Although at screening, this patient was
eligible for the trial, when his serial antecedent results were
reviewed it was clear that his renal function was fluctuating. His
renal function was probably suboptimal following drug adminis-
tration, resulting in markedly elevated AUC for free platinum
compared with patients treated at the same dose level.
The Cmax (maximum concentration) also increased linearly with
dose. The mean terminal half-life (t1/2) for free platinum was 85h
at dose level 120mgm
 2, which was longer than that seen in mice
(10h). At lower dose levels, the t1/2 was also apparently lower,
attributable to the insensitivity of the pharmacokinetic assay and
Table 3 Incidence of grades 3, 4 haematological toxicity with AMD473 given as an intravenous infusion, for cycle one and overall
(a) Incidence during the first cycle
Dose level, total patients treated at this dose level
12, 24,
48mgm
 2 96mgm
 2 130mgm
 2 110mgm
 2 150mgm
 2 120mgm
 2
Toxicity N=9 N=3 N=5 N=5 N=6 N=14
Haematological
Anaemia 0 0 1 0 0 0
Thrombocytopenia 0 0 2** 0 3*** 0
Leucopenia 0 2 0 2 0
Neutropenia 0 0 2 0 3 0
Neutropenic sepsis 0 0 0 0 0 0
Lymphopenia 0 1 2 1 0 3
Nonhaematological
Emesis 0 1 0 1 0 0
Malaise 0 0 0 0 0 1*
(b) Incidence overall
Dose
Total
number of
cycles
WCC,
number of
cycles
affected (%)
Neutrophils,
number of
cycles
affected (%)
Platelets,
number of
cycles
affected (%)
Hb, number
of cycles
affected (%)
12 11 0 0 0 0
24 10 0 0 0 0
48 9 0 0 0 0
96 12 1 1 1 1
110 19 1 3 (15.8) 2 (10.5) 0
120 48 2 (4.2) 5 (10.4) 6 (12.5) 2 (4.2)
130 12 2 (16.7) 2 (16.7) 3 (25) 1 (8.3)
150 26 4 (15.4) 6 (23.1) 12 (46.2) 3 (11.5)
*Each represents a DLT event.
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sunderestimation of plasma concentrations at later time points. The
mean proportion of free platinum excreted in the urine was 32.9%
(715.9 s.d.) overall over 36h (34.2710.3% at 120mgm
 2). At
120mgm
 2, there was a moderate negative correlation between the
ultrafiltrable platinum AUC and calculated creatinine clearance.
(r
2¼0.47, Po0.0001) (Figure 3).
There was no significant correlation between the percentage
decrease of platelets or neutrophils with either AUC or Cmax of free
platinum. The closest relation appears to be between Cmax for free
platinum and the percent decrease in platelets (r
2¼0.51,
Po0.0001) (Figure 4).
Antitumour activity
The best response to treatment in all patients is listed in Table 6.
One patient with carcinoma of the ovary showed a radiological
partial response after four cycles of treatment associated with a fall
in her CA125 from 440 to 16Uml
 1. This patient was particularly
heavily pretreated and, because of thrombocytopenia, her first
cycle of the study drug was given at 150mgm
 2, a second cycle at
120mgm
 2, a third cycle at 96mgm
 2, followed by her fourth to
eighth cycles, inclusive, at 80mgm
 2. Another patient with
ovarian cancer had a partial response after two cycles, but this
Table 4 Mean and s.d. pharmacokinetic values: ultrafiltrable platinum, after administration of AMD473 as intravenous infusion
Dose
(mgm
 2)
Cmax
mean
(lgl
 1) s.d.
AUClast
mean
(hlgl
 1) s.d.
AUCinf
mean
(hlgl
 1) s.d.
t1/2c
mean
(h) s.d.
Clobs
mean
(lh
 1) s.d.
Vssobs
mean
(l) s.d.
12 353 48 896 522 985 655 12.3 18.6 13.9 7.0 78.6 88.5
24 676 90 1284 305 1308 322 3.2 3.1 17.7 3.6 37.5 6.5
48 1216 203 2598 148 3062 175 31.9 15.1 15.2 0.8 303.1 153.4
96 3197 326 7170 1214 7642 1359 50.9 14.5 12.1 3.4 286.3 43.6
110 3142 890 7919 2436 8717 2765 49.3 28.5 8.3 1.6 369.1 260
120 3250 647 11139 5183 13078 6360 85.7 38.9 12.4 3.9 560.3 340.3
130 3636 955 10407 1441 13318 3241 96.5 63.6 10.2 4.2 502.4 342.8
150 3740 1101 12604 3713 13960 4301 67.5 25.2 11.0 3.8 462.2 70.6
s.d.=standard deviation, AUClast=area under the dose concentration curve to last time point, AUCinf=area under the dose concentration curve extrapolated to infinity,
t1/2g=terminal half-life, Clobs=observed clearance, Vssobs=volume of distribution at steady state.
Table 5 Mean and s.d. pharmacokinetic values: plasma total platinum, after administration of AMD473 as intravenous infusion
Dose
Cmax
mean
(lgl
 1) s.d.
AUClast
mean
(hlgl
 1) s.d.
t1/2c
mean
(h) s.d.
Clobs
mean
(lh
 1) s.d.
Vssobs
mean
(l) s.d.
12 565 48 12671 233 138 92 0.57 0.25 92.3 10.5
24 923 112 24535 3993 107 52 0.67 0.21 89.3 9.78
48 1327 236 51205 11040 111 54 0.67 0.19 99.3 46.2
96 3567 321 88407 30511 182 94 0.48 0.21 102.8 7.9
110 3600 1420 77885 33802 118 87 1.0 0.64 117.9 45.9
120 4823 1022 171011 34890 160 80 0.41 0.16 82.4 25.9
130 5768 3071 164685 88378 131 40 0.41 0.28 63.0 16.05
150 5760 1352 204201 31883 171 49 0.41 0.16 91.3 24.2
s.d.=standard deviation, AUClast=area under the dose concentration curve to last time point, AUCinf=area under the dose concentration curve extrapolated to infinity,
t1/2g=terminal half-life, Clobs=observed clearance, Vssobs=volume of distribution at steady state. AUCinf=area under the dose concentration curve extrapolated to infinity is not
given as this is an inappropriate and unreliable parameter when considering bound drug (total platinum).
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swas not confirmed with a second CT scan, although there was a
sustained 450% reduction in CA125. Five other patients had
stable disease after multiple cycles of treatment; these patients had
mesothelioma, ovarian carcinoma, nonsmall cell lung cancer, and
melanoma. A further patient with mesothelioma, whose disease
was not evaluable, experienced significant clinical benefit. This was
demonstrated by a reduction in his pain and an improvement in
respiratory and effort capacity. The combined effect of this allowed
him to return to work.
DISCUSSION
This study shows that AMD473 is devoid of significant organ-
specific toxicity, and has predictable, dose-limiting myelosuppres-
sion and linear pharmacokinetics, as predicted by preclinical
studies. The MTD is 150mgm
 2, with myelosuppression, particu-
larly thrombocytopenia, being dose-limiting. The dose recom-
mended for second-line treatment in a phase II study is 120mgm
 2
given every 21 days, based on expanded accrual in a less heavily
pretreated population. However, our results show that two factors
play an important role in determining the degree of toxicity
observed, namely the extent of prior myelosuppressive chemother-
apy and the performance status. As a consequence, there will be a
group of patients (i.e. those who are relatively chemo-naive with
ECOG performance status 0, 1) who will be able to tolerate higher
doses (e.g. 150mgm
 2 q 21 days) with minimal added toxicity.
Conversely, those patients who have received extensive prior
chemotherapy and/or have a performance status of X2 may not
be able to receive the drug on a 3-week schedule. This
recommendation has been confirmed in the clinical experience
seen in the Phase II setting to date. Escalation to 150mgm
 2 every
21 days has proved deliverable in patients with pretreated small
cell, breast and ovarian cancers, but who are still relatively
chemo-naive. However, the degree of myelosuppression at this dose
level is higher and requires surveillance, as dose modifications are
not infrequent (Bonhomi et al,2 0 0 1 ;V a n d e n b e r get al, 2001; Gore
et al,2 0 0 2 ) .
There was a linear relation between dose and both Cmax and
AUC for ultrafiltrable and total platinum. Renal excretion was
approximately 30%. Referring back to the preclinical models, the
AUC (ultrafiltrate) for the mouse at the MTD (45mgkg
 1E
135mgm
 2) was 9844mgPt(lh)
 1 (Pre-clinical report CR UK,
1997). This is very close to that seen at 130mgm
 2 in the current
study in man, with an AUC (ultrafiltrate) of 10407mgPt(lh)
 1
(ratio 0.95). The ratio is similar to that of other platinum species
and suggests that the method of dose escalation used in this study
was appropriate for AMD473. It also gives confidence that the
exposure achieved in man (and therefore potential anticancer
activity) is equivalent to that seen in the mouse models (Raynaud
et al, 1997). In contrast to some other recently investigated novel
platinum compounds such as satraplatin, AMD473 is not subject to
extensive degradative metabolism (McKeage et al, 1995; Raynaud
et al, 1996; Judson et al, 2000).
No clear relation could be shown between any pharmacokinetic
parameters and toxicity other than a weak correlation between
thrombocytopenia and peak platinum concentration achieved.
This is in line with the findings reported by Stevenson et al (2001).
Using an alternative, arguably more specific pharmacokinetic
assay – stable isotope dilution liquid chromatography/tandem
mass spectrometry, evidence for a pharmacokinetic/pharmaco-
dynamic relation following AMD473 intravenous infusion was
limited other than some evidence for a correlation between
thrombocytopenia and AUC(0 t) (Stevenson et al, 2001). Atomic
absorption spectrophotometry was used in our current study as
this was the method used in the preclinical work with AMD473. As
is the case with many Phase I studies, the sensitivity of the assay is
stretched at the lower dose levels dictated by a safe starting dose,
but with an LLQ of 5ngml
 1 the assay was considered to be more
than sensitive enough to measure the study compound at
therapeutic levels and to perform pharmacokinetically guided
dose escalation.
The toxicity profile was similar to that of carboplatin, rather
than cisplatin, and toxicity did not appear to be cumulative, with
the possible exception of anaemia. The degree and duration of
thrombocytopenia and neutropenia were predictable. Emesis
appears to be moderate and can be controlled with a 5-HT3
antagonist and dexamethasone.
The DLT, not unexpectedly, proved to be myelosuppression with
thrombocytopenia predominating. The patient who died from
rectal bleeding while thrombocytopenic was felt to have died from
disease progression rather than drug toxicity. However, a second
patient did withdraw from treatment owing to similar toxicity.
Neutropenia also occurred, commonly following the development
of thrombocytopenia. Delay in neutrophil recovery did lead to
dose delay in some patients. However, there was only one episode
of neutropenic sepsis requiring hospitalization, occurring in a
patient with a long-standing ureteric stent.
There was no evidence of ototoxicity (as assessed by audiogram)
or symptomatic neurotoxicity, although some patients reported a
change in taste, characteristically metallic in nature. Formal nerve
conduction studies were not performed. No deterioration in serum
creatinine or in calculated creatinine clearance was observed;
however, serial
51Cr EDTA evaluations were not performed.
There was evidence of activity in ovarian cancer despite prior
therapy with platinum. Preclinical studies suggested that AMD473
could overcome acquired resistance to platinum complexes.
Certainly in this Phase I trial there was evidence of antitumour
activity in a relatively heavily pretreated patient population. Early
results from Phase II investigations conducted in nonsmall cell
lung cancer, small cell lung cancer, and ovarian cancer suggest that
AMD473 does have activity in patients who have received prior
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Figure 4 Decrease in platelets vs Cmax free platinum.
Table 6 Summary of best response achieved to treatment with
AMD473 as intravenous infusion
Best response No. of patients (%)
Partial response 1 (2.4)
Stable disease 6 (14.3)
Early progression 3 (7.1)
Progressive disease 12 (28.6)
Not evaluable 19 (45.2)
Not assessed 1 (2.4)
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schemotherapy, including those who have received platinum-
containing regimens (Bonomi et al, 2001; Quoix et al, 2001; Gore
et al, 2002). The clinical utility of this activity will require further
clinical trials in appropriate patient populations. In such studies, it
will be important to maximise treatment intensity relevant to the
population under evaluation.
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